Table 3.
Comparison of the clinicopathological features between mucinous breast cancer (MBC) and invasive carcinoma of no special type (NST).
| MBC | NST | p | |||
|---|---|---|---|---|---|
| No. of patients | % | No. of patients | % | ||
| Age | 0.009 | ||||
| Median | 65.5 | 60.0 | |||
| Average | 66.0 | 60.0 | |||
| Range | 35–88 | 27–91 | |||
| ≤ 30 | 0 | 0.0 | 5 | 0.8 | |
| 31–40 | 1 | 4.2 | 29 | 4.9 | |
| 41–50 | 2 | 8.3 | 92 | 15.5 | |
| 51–60 | 4 | 16.7 | 186 | 31.4 | |
| 61–70 | 6 | 25.0 | 165 | 27.9 | |
| 71–80 | 9 | 37.5 | 87 | 14.7 | |
| ≥ 81 | 2 | 8.3 | 28 | 4.7 | |
| Median size | 2.19 cm | 1.92 cm | 0.018 | ||
| OS 5-year (%) | 95.8% | 75.3% | 0.013 | ||
| DFS 5-year (%) | 91.6% | 70.2% | 0.011 | ||
| Local recurrence (%) | 8.3% | 29.8% | 0.004 | ||
| Tumor size (T) | 0.748 | ||||
| T1a | 1 | 4.2 | 12 | 2.0 | |
| T1b | 2 | 8.3 | 54 | 9.1 | |
| T1c | 10 | 41.7 | 232 | 39.2 | |
| T2 | 9 | 37.5 | 248 | 41.9 | |
| T3 | 0 | 0.0 | 9 | 1.5 | |
| T4 | 2 | 8.3 | 37 | 6.3 | |
| Nodal status (pN) | 0.007 | ||||
| pN0 | 21 | 81.7 | 354 | 59.8 | |
| pN1 | 2 | 8.3 | 142 | 24.0 | |
| pN2 | 1 | 4.2 | 63 | 10.6 | |
| pN3 | 0 | 0.0 | 33 | 5.6 | |
| Tumor grade | 0.005 | ||||
| G1 | 0 | 0.0 | 46 | 7.8 | |
| G2 | 22 | 91.7 | 321 | 54.2 | |
| G3 | 2 | 8.3 | 189 | 31.9 | |
| Gx (necrosis/autolysis) | 0 | 0.0 | 36 | 6.1 | |
| Estrogen receptor status | 0.474 | ||||
| ER− | 7 | 29.2 | 215 | 36.3 | |
| ER+ | 17 | 70.8 | 377 | 63.7 | |
| Progesterone receptor status | 0.925 | ||||
| PR− | 9 | 37.5 | 241 | 40.7 | |
| PR+ | 15 | 62.5 | 351 | 59.3 | |
| HER2 status | 1.000 | ||||
| HER2 0/1+ | 20 | 83.3 | 488 | 82.4 | |
| HER2 2+ | 0 | 0.0 | 32 | 5.4 | |
| HER2 3+ | 4 | 16.7 | 72 | 12.2 | |
| Stage (TNM) | 0.037 | ||||
| I | 4 | 16.7 | 262 | 44.3 | |
| II | 9 | 37.5 | 224 | 37.8 | |
| III | 11 | 45.8 | 77 | 13.0 | |
| IV | 0 | 0.0 | 29 | 4.9 | |